Table 2.

Estimated number of patients potentially eligible from carbon ion radiotherapy in 2015 and 2019.

Disease site	2015 cases in the United States, No.	Patients eligible for CIRT in 2015, No. (%)	Estimated 2019 cases [1, 2], No.	Estimated patients eligible for CIRT in 2019, No. (%)
Glioblastoma	19 840	4335 (21.8)	23 820	5205 (21.9)
Head and neck	6606	5177 (78.4)	5300	4154 (78.4)
Hepatocellular carcinoma	18 735	13 872 (74.0)	42 030	31 120 (74.0)
Cholangiocarcinoma	5368	1753 (32.7)	12 360	4036 (32.7)
Pancreas	35 188	17 786 (50.5)	56 770	28 695 (50.5)
Non–small cell lung cancer	127 272	72 417 (56.9)	228 150	129 816 (56.9)
Prostate	104 072	85 710 (82.4)	174 650	143 836 (82.4)
Soft tissue sarcomas	8985	6846 (76.2)	16 250	12 381 (76.2)

The number of 2015 cases was estimated based on our analysis of the NCDB. The number of patients eligible in 2015 was based on inclusion criteria using trials for Asia and Europe. The estimated number of eligible patients in 2019 was based on taking the percentage of patients eligible in 2015 and applying that to the 2015 data. Please see the text for details regarding the specific calculation.